Sun Pharma flags slower FY27 growth after 12% FY26

FY27 guidance shifts to high single-digit growth

Sun Pharmaceutical Industries has guided for slower revenue growth in FY27 after delivering double-digit expansion in FY26. The company cited the current regulatory and macro environment as the key constraint on near-term momentum. Executive chairman Dilip Shanghvi told analysts the company expects “high single-digit consolidated top-line growth” in FY27. The commentary came during a post-earnings call after Sun Pharma reported its Q4FY26 and full-year FY26 results. The guidance matters because it signals moderation after a strong year for India’s largest pharma company by revenue and market capitalization. It also frames investor expectations around launches, approvals, and pricing conditions, especially in the US market.

FY26 performance: revenue up 11.9%, profit up 5%

For FY26, Sun Pharma reported consolidated revenue of ₹58,220 crore, up 11.9% year-on-year. Consolidated net profit rose 5% year-on-year to ₹11,479.4 crore. Management attributed growth to gains in India, its largest market, along with performance from its innovative portfolio in the US and contributions from non-US markets. India sales grew 14% in FY26 to ₹19,290.4 crore, highlighting the continued strength of the domestic branded formulations business. The company’s scale across therapies and geographies helped it post growth despite ongoing pressures in parts of the global generics segment.

Q4FY26: revenue growth continues, margins tighten

In the March quarter, Sun Pharma’s revenue from operations increased 13.6% year-on-year to ₹14,559.8 crore. Net profit for the quarter rose 26.2% to ₹2,714 crore, showing a stronger bottom-line performance versus the full-year growth rate. Quarterly Ebitda stood at ₹3,954.2 crore, up 6.4% over the year-ago period. However, Ebitda margin contracted by 160 basis points to 27.1%, indicating cost or mix pressures even as revenue expanded. These quarter-specific margin dynamics were part of the broader context investors assessed alongside the FY27 guidance.

India business: 33.2% of Q4 revenue, led by key therapies

Sun Pharma said its India business grew 14.8% in Q4FY26 to ₹4,835.9 crore. The India business accounted for 33.2% of the company’s overall business during the quarter, underscoring its role as a stabilising earnings base. Growth was led by the central nervous system (CNS), cardiovascular, gastro, and ortho segments. The domestic market’s performance was a key support as the company navigates a tougher US generics environment. Strong India growth in both FY26 and Q4FY26 also explains why management continues to emphasise portfolio depth and execution in core therapies.

Innovative portfolio: global growth and a US milestone

A key highlight discussed on the call was the innovative medicines franchise. In Q4FY26, innovative medicines sales globally stood at $154 million, up 20.1% year-on-year. Separately, Richard Ascroft, CEO of the North America business, said innovative medicines crossed $1.1 billion in sales for the first time in the US. The company’s management also pointed to strong momentum in the innovative business in other markets and cited a strong pipeline as supportive for growth. This narrative positions innovation as an important counterweight to US generics headwinds, especially when regulatory actions affect approvals.

US formulations and generics: pressure points remain

Sun Pharma reported that US formulations declined marginally to $159 million in the fourth quarter. On the generics side, Shanghvi told analysts that delays in approvals due to compliance issues, along with continued pricing pressure in the US, affected the generics business. He added that the company expects improvement as new approvals start coming through. The comments suggest that while the company is working through operational constraints, the timing of regulatory outcomes remains a swing factor for performance. This is also why the FY27 growth outlook is presented cautiously, despite the strong FY26 base.

Slowing momentum: fewer large launches expected in FY27

Analysts said the FY27 guidance reflects moderation, driven largely by fewer planned launches. Vishal Manchanda, pharma analyst at Systematix Group, said there are no large launches expected in FY27, and the focus will be on ramping up launches done in FY26. In FY26, Sun Pharma launched two specialty drugs in the US: alopecia areata drug Leqselvi in July 2025 and cancer drug Unloxcyt in January 2026. The company had announced a $100 million one-time marketing spend for these in FY26. Manchanda said FY27 will involve a continued push for these drugs in the US and scaling up the base portfolio through new geography expansion, while he does not see a lever in US generics for the year.

Compliance issues at three sites and their approval impact

The company’s US execution is also tied to its manufacturing compliance status. Sun Pharma has ongoing compliance issues at three key manufacturing sites: Halol, Mohali, and Dadra. The article links these issues to delays in approvals, which in turn weigh on the pace of new product flow into the US market. Management’s position, as conveyed on the call, is that improvement should follow as approvals resume. For investors, this places regulatory remediation and approval timelines at the centre of near-term monitoring, alongside the broader pricing environment.

R&D spend and Organon acquisition: building specialty and biosimilars

Sun Pharma said it expects to spend 6%-7% of sales on R&D in FY27, similar to the 6.1% spent in FY26. The company has five novel entities in the clinical stage, along with several generics filings in its R&D pipeline. Alongside internal development, Sun Pharma is also leaning on acquisitions to strengthen its specialty portfolio. Last month, it announced an $11.75 billion acquisition of US-based women’s healthcare and biosimilars company Organon & Co. Sun Pharma expects the deal to be completed by the fourth quarter of the current fiscal. The acquisition is expected to complement Sun’s branded generics business in several markets and strengthen its entry into women’s innovative medicines and biosimilars.

Obesity drugs in India: semaglutide rollout still evolving

Sun Pharma is also targeting India’s growing obesity-drug market. The company is among several Indian drugmakers that launched generic semaglutide in India in March 2026 after the drug lost patent exclusivity. However, it is yet to emerge among the top three players in India’s semaglutide market. A company executive, Ganorkar, said that with any new product launch it takes time for the full sales reflection to show up, and that in the next 5-6 months the “reflection” will be closer to reality. The comment signals that near-term ranking may not fully capture the company’s eventual scale-up in this category.

Dividend, stock reaction, and what investors are watching

Sun Pharma’s board proposed a final dividend of ₹5 per share for FY26, in addition to an interim dividend of ₹11 per share paid in FY26. This takes the total FY26 dividend to ₹16 per share, the same as FY25. The results were announced during market hours on Friday, and the stock closed 2.71% lower at ₹1,840 on the NSE. It underperformed the Nifty Pharma index, which closed 1.27% lower. The immediate market reaction aligns with the guidance-driven reset in growth expectations, even as FY26 numbers remained robust.

Key numbers at a glance

Conclusion: strong base, cautious outlook

Sun Pharma enters FY27 after a year of 11.9% revenue growth and rising India and innovative-medicines momentum. But management has guided to high single-digit growth, citing regulatory and macro conditions, while analysts point to fewer large launches in the year. Near-term performance will be shaped by the pace of approvals amid compliance issues at Halol, Mohali, and Dadra, and by pricing trends in the US. Investors will also track execution on the Organon acquisition, expected to close by Q4 of the current fiscal, and the company’s ability to scale recent specialty launches and newer segments such as obesity therapies in India.